Next Phase Newsletter

A family office based in Birmingham, Alabama invests in a number of sectors, including healthcare, real estate, and finance. The firm typically makes co-investments between $100,000 and $3 million, and looks to make 5-6 investments within the next year. The firm is open to investments globally.

The firm is open to all sectors and subsectors of life science—biotech therapeutics, medical devices, diagnostics, and healthcare IT. The firm is agnostic in terms of indications and is open to all phases of development.

The firm requires companies to have a management team set in place, and will help fill the board, if necessary.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A healthcare-focused, evergreen fund based in California is looking for new life science opportunities. The firm is mainly focused on therapeutics and will consider platform technologies, however only platforms capable of generating drug candidates. The firm’s investment size varies widely depending on the needs of the company, and will make investments of up to $5M. The capital structure depends on the financing round, with convertible notes being preferred for seed rounds and equity for everything else; no debt financing. The firm only co-invests, and does not lead rounds. The firm has some limitations on geographic exposure and will consider companies in any part of the U.S., Western Canada or England.

The firm invests in therapeutics that treat rare and ultra-rare/orphan diseases. The firm is interested in earlier stage assets and will consider anything from preclinical up unto phase IIa. In the past, the firm has invested in therapeutics, which treat unmet needs in glaucoma, patients with prosthetic heart valves and renal dysfunction as well as a small molecule to treat Alzheimer’s disease. The firm will consider early-stage therapeutics to treat orphan disease including small molecules, biologics, repurposed drugs or biosimilars, cell/gene therapy candidates (least interest) and platform technologies (that generate drug candidates). The firm is not interested in diagnostics, medical devices or healthcare IT.

The firm does not have any specific management team requirements, and will work with all entrepreneurs. A board seat is not always required, but is not uncommon.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A global private equity firm based in California has over $50 billion AUM and invests across development stages, from early to late stages. The firm’s investment size is highly variable depending on the stage of the company, ranging from $1M to $25M in equity. The firm has a global mandate and is actively seeking new investment opportunities.

The firm seeks compelling investment opportunities in drug discovery and development platforms developing novel therapeutics, medical devices, healthcare services and healthcare IT. For therapeutics, the firm seeks small molecules and biologics and is open to all indications including orphan indications. The firm will consider products in all phases of clinical trials, from pre-clinical to phase III, and also commercial stage therapeutics. The firm is open to both PMA and 510K devices, as long as the device is already being sold at a commercial stage. The firm is also interested in services such as CROs and CMOs as well as tools of genomics and proteomics.

The firm invests for the long term, and is heavily involved in, and committed to, the growth and success of their portfolio companies. The firm therefore generally take a board seat/observer rights. The firm only invests in private companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A specialist healthcare company with offices worldwide is looking to in-license and acquire therapeutics and medical devices that are of strategic interest. The firm is capable of making allocations ranging from £10 million to over £100 and more for later stage acquisitions. The firm is primarily interested in companies that are looking to be marketed in the United States although they are open to global opportunities as well.

The firm is interested in Therapeutic assets and Medical Devices. For therapeutics the firm’s current products include antidotes to treat snake envenomation and toxicity associated with medicines used for heart conditions and cancer. The firm is open to therapeutics within these areas as well as other indications pending they are intended to be hospital products. The firm primarily focuses on small molecule therapeutics. For medical devices the firm is looking for companies that have 510 K approval in Oncology, Vascular and Pulmonary fields. The firm’s current device products include Interventional Oncology products used to treat patients with liver tumors and Interventional Vascular products used to treat patients with severe blood clots.

The firm is interested in working with founding management teams prior to investment and is open to in-licensing from public and private clients.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A global private equity and corporate finance advisory firm is headquartered in Singapore with offices in India, Malaysia and London. The firm makes global investments into life science companies as well as services related to healthcare. The firm leads the round with a $0.5m – $10m investment and utilizes their network to seek out other co-investors. The firm will occasionally seek distribution rights for international investments.

The PE firm is interested in therapeutics, medical devices, diagnostics, healthcare IT, biotech R&D services and suppliers and engineering companies. The firm is both stage and indication agnostic and has no revenue requirement. The firm has flexible investment criteria but the East West Axis is very important as the firm is not interested in companies that are restricted to one country; the firm only looks for companies with a multinational, global component.

The PE firm is flexible with their management team requirements. The firm is open to bringing in their own talent to assist with management and have assisted scientists in becoming successful entrepreneurs. The firm is a value-added investor driven by opportunity. The firm takes a board seat when making investments.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A hedge fund with offices in New York and Miami looks to make 3-4 new equity investments into commercial-stage companies located from all geographies, however – the firm likes to see companies with commercial sales in North America and/or Europe. The firm cares less about company headquarters and more about where its products are approved and sold. For companies with enterprise values of $20M – $200M, the firm commits $5M – $20M and is willing to lead rounds or join syndicates as long as the investment gives a meaningful stake in the company for the purposes of being able to add value.

The fund is interested in medical devices and diagnostics. Within medical devices, the firm prefers devices with strong IP protection and generally with PMA or 510(k) approval. Within diagnostics, the firm is very opportunistic though their recent experience has focused on cancer genomic testing. The fund is open to all indication areas but historically has focused on cardiovascular, oncology and minimally invasive surgery.

The fund looks for seasoned management teams that have relevant experience in the sector the company is involved in. The firm likes to see this across the C-suite, particularly in the CEO and sales and marketing leadership. The firm takes a board seat when making investments and looks to add value through active involvement.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A biopharmaceutical company based in Asia seeks research collaboration, in-licensing, and partnering opportunities with companies mainly in the oncology space. The firm seeks 3-5 projects within the next year. The firm has a “no research, development only” model, and licenses drug candidates ranging from preclinical to clinical stages. The firm currently has projects from the USA and Europe, though is open to projects globally.

The pharma firm seeks biotech therapeutics in oncology and Asian prevalent diseases, such as hepatoma (liver cancer), soft tissue sarcoma, as well as other local diseases in Asia. The firm will consider therapeutics in all phases, and has a particular interest in small biotech companies.

The firm prefers a management team with experience in oncology and other relevant fields of science. As a public company, the firm will partner with the company and collaborate with its research and development.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com